Sight Sciences, Inc. (SGHT)
After hours:
| Previous close | 5.37 |
| Open | 5.24 |
| Bid | 5.58 x 100 |
| Ask | 5.73 x 100 |
| Day's range | 5.24 - 5.87 |
| 52-week range | 1.04 - 11.20 |
| Volume | |
| Avg. volume | 186,030 |
| Market cap | 279.481M |
| Beta (5Y monthly) | 2.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.63 |
Simply Wall St.With 34% ownership, Sight Sciences, Inc. (NASDAQ:SGHT) has piqued the interest of institutional investors
Key Insights Given the large stake in the stock by institutions, Sight Sciences' stock price might be vulnerable to...
GlobeNewswireSight Sciences to Report First Quarter Financial Results on May 2, 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company’s management will discuss the results during a conference call beginnin
- GlobeNewswire
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared in over 100,000 glaucoma patient eyesMENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announ
